Salsalate Attenuates Free Fatty Acid–Induced Microvascular and Metabolic Insulin Resistance in Humans by Chai, Weidong et al.
Salsalate Attenuates Free Fatty
Acid–Induced Microvascular and
Metabolic Insulin Resistance in Humans
WEIDONG CHAI, MD, PHD
JIA LIU, BS
LINDA A. JAHN, MS
DALE E. FOWLER, MD
EUGENE J. BARRETT, MD, PHD
ZHENQI LIU, MD
OBJECTIVE—Insulin recruits muscle microvasculature, thereby increasing endothelial ex-
change surface area. Free fatty acids (FFAs) cause insulin resistance by activating inhibitor of kB
kinase b. Elevating plasma FFAs impairs insulin’s microvascular and metabolic actions in vivo.
Whether salsalate, an anti-inﬂammatory agent, prevents FFA-induced microvascular and/or
metabolic insulin resistance in humans is unknown.
RESEARCH DESIGN AND METHODS—Eleven healthy, young adults were studied
three times in random order. After an overnight fast, on two occasions each subject received a
5-h systemic infusion of Intralipid 6 salsalate pretreatment (50 mg/kg/day for 4 days). On the
third occasion, saline replaced Intralipid. A 1 mU/kg/min euglycemic insulin clamp was super-
imposedoverthelast2-hofeachstudy.Skeletalandcardiacmusclemicrovascularbloodvolume
(MBV), microvascular ﬂow velocity (MFV), and microvascular blood ﬂow (MBF) were deter-
mined before and after insulin infusion. Whole bodyglucose disposal rates were calculated from
glucose infusion rates.
RESULTS—Insulin signiﬁcantly increased skeletal and cardiac muscle MBV and MBF without
affecting MFV. Lipid infusion abolished insulin-mediated microvascular recruitment in both
skeletal and cardiac muscle and lowered insulin-stimulated whole body glucose disposal (P ,
0.001). Salsalate treatment rescued insulin’s actions to recruit muscle microvasculature and
improved insulin-stimulated whole body glucose disposal in the presence of high plasma FFAs.
CONCLUSIONS—High plasma concentrations of FFAs cause both microvascular and met-
abolic insulin resistance, which can be prevented or attenuated by salsalate treatment. Our data
suggest that treatments aimed at inhibition of inﬂammatory response might help alleviate vas-
cular insulin resistance and improve metabolic control in patients with diabetes.




of cardiovascular complications in
patients with type 2 diabetes. Among
many contributing factors, free fatty
acids (FFAs) have been implicated as
the key culprit. As major oxidative fuels
for heart and resting muscle, plasma
levels of FFAs are elevated in patients
with diabetes and they induce insulin
resistance, inﬂammation, and vascular
dysfunction.
In cultured endothelial cells (ECs),
the inhibitor of kBk i n a s eb (IKKb)
appears to be the common effector in
FFA-mediated vascular insulin resistance
and inﬂammation, as transfection of the
ECs with a dominant negative IKKb ab-
rogates FFA-mediated insulin resistance,
whereas overexpression of wild-type
IKKb recapitulates the effect of FFAs
(1). IKKb is a serine kinase that controls
the activation of nuclear factor-kBa n d
is a critical link between inﬂammation
and insulin resistance (2–4). To date,
evidence strongly suggests that FFAs
induce inﬂammation, which contrib-
utes to the pathogenesis of insulin resis-
tance and endothelial dysfunction in
diabetes.
We have previously shown that in-
sulin at physiological concentrations
potently increases microvascular recruit-
ment in both cardiac (5,6) and skeletal
muscle (6,7) in humans. Insulin’s vasodi-
latory effect appears to be mediated
throughthephosphatidylinositol3-kinase
(PI3-kinase)/protein kinase B/endothelial
nitric oxide (NO) synthase (eNOS) path-
way (8). This insulin-mediated microvas-
cular recruitment is impaired in the
presence of high plasma concentrations
of FFAs (6,7,9). Whether inﬂammation
is involved in this FFA-induced microvas-
cular insulin resistance is not clear.
In the current study, we examined the
effect of salsalate, an anti-inﬂammatory
agent that inhibits IKKb, on lipid-induced
microvascularand metabolic insulinresis-
tance in healthy humans. Our results
suggest that lipid likely induces microvas-
cular and metabolic insulin resistance in
humans via an inﬂammation-mediated
mechanism,assalsalatetreatmentrestored
muscle microvascular insulin response,
which was associated with decreased met-
abolic insulin resistance in the presence of




Young, healthy subjects with no history of
obesity, hypertension, diabetes, or hyper-
lipidemia were screened in the General
Clinical Research Center (GCRC) at the
University of Virginia. Prothrombin time,
partial prothrombin time, complete blood
counts, lipid proﬁles, insulin, and glucose
were measured. Height and weight were
measured and the BMI was calculated.
Exclusion criteria included pregnancy,
smoking, anemia, bleeding tendency, tak-
ing medications or supplements that are
known to affect endothelial function and/or
glucose metabolism, and family history of
diabetes in a ﬁrst-degree relative.
A total of 11 (8 men, 3 women)
subjects (age 21.7 6 0.4 years, BMI
23.2 6 0.7 kg/m
2) were recruited and
studied three times in the GCRC. All sub-
jects provided written informed consent
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Pathophysiology/Complications
ORIGINAL ARTICLEat the screening visit, and the study pro-
tocol was approved by the University of
Virginia Institutional Review Board and
the GCRC Advisory Committee.
Ateach study,subjectswere admitted
the evening before and fasted overnight.
On the morning of the study, one intra-
venous catheter was placed in the right
antecubital vein for the infusion of nor-
malsaline,Intralipidwithheparin,micro-
bubbles, insulin, and glucose. A second
intravenous catheter was placed in the
right hand for blood sampling of glucose,
FFAs, and insulin. Subjects were studied
under the following three protocols in
random order, with at least 2 weeks be-
tween admissions (Fig. 1A).
Saline (control) protocol. After obtain-
ingbaselinebloodsamples,baselineskel-
etal and cardiac muscle microvascular
parameter measurements—including
microvascular blood volume (MBV) and
microvascular ﬂow velocity (MFV)—were
determined using contrast-enhanced ultra-
sound (CEU) and myocardial contrast
echocardiography (MCE), and microvas-
cular blood ﬂow (MBF) was calculated
(see below). Each subject then received
a 2-h intravenous infusion of regular
insulin (2 mU/min/kg 3 10 min and
1mU/min/kg3110min).Plasmaglucose
wasmeasuredevery5minthroughoutthe
insulin infusion, and 20% dextrose was
infused atvariable rates tomaintaineugly-
cemia. Skeletal and cardiac muscle MBV
and MFV were again measured, and MBF
was calculated at the end of the 120 min
insulin clamp. Plasma insulin and FFAs
were measured at 0, 30, 60, 90, and
120 min.
Lipid protocol. The lipid study was
carried out in the exact same fashion as
thesalinecontrolprotocolexceptthatall
subjects received intravenous infusion
of Intralipid (20%, 45 mL/h) and heparin
(0.2units/kg/min)foratotalof5h.Heparin
wasgiventoactivateendotheliallipoprotein
lipase to facilitate the conversion of cir-
culating lipids to FFAs. The insulin clamp
was started 3 h after the initiation of the
Intralipid/heparin infusion and the CEU/
MCEmeasurementsweredoneimmediately
before and at 120 min of insulin infusion.
Salsalate plus lipid protocol. The
salsalate plus lipid study was identical to
the lipid protocol except that all subjects
received salsalate 25 mg/kg twice a day
by mouth for 4 days prior to study.
The last salsalate dose was given at time
2180 min on the day of study (Fig. 1A).
Plasma salicylate concentrations were
22 6 1 mg/dL at time 2180 min (prior
to the last dose) and 25 6 2m g / d La t
time0min(3hafterthelastdose),suggest-
ingthattheplasmasalsalateconcentrations
had reached a relative steady state. This
dose was well tolerated by all subjects.
Imaging procedure and analyses
CEU and MCE were performed using a
SONOS 7500 ultrasound system and an
S3 phased array transducer (Philips Med-
ical Systems, Andover, MA) while the
subject was in the left decubitus position,
as previously described (5,7). In brief,
the contrast agent (Deﬁnity, Lantheus
Medical Imaging, North Billerica, MA)
was infused intravenously, and after the
systemic microbubble concentrations
reached steady state (;3 min), intermit-
tent imaging of the forearm was per-
formed in a transaxial plane 5 cm distal
to the antecubital fossa using ultrahar-
monic imaging with pulsing intervals
(PIs) ranging from 1 to 20 s. Immediately
after the forearm muscle CEU imaging,
myocardial microvascular imaging was
done using intermittent ultraharmonic
imaging from the apical 4-, 2-, and
3-chamber windows, with ultrasound
transmitted at 1.3 MHz and received at
3.6 MHz and PIs of 1, 2, 3, 4, 5, and
8 cardiac cycles. Three images were cap-
tured at each PI. All muscle and cardiac
images were blindly analyzed using QLAB
software (Philips Medical Systems) by
W.C. and J.L., as described previously
(5,7). MBF is derived from the product of
MBV and MFV (i.e., MBF = MBV 3 MFV).
Biochemical analysis
Plasma cholesterol, HDL cholesterol, and
triglycerideswereassayedbytheUniversity
of Virginia clinical chemistry laboratories.
Plasma glucose was measured using a YSI
glucose analyzer (Yellow Springs Instru-
ments, Yellow Springs, OH). Plasma in-
sulin was determined using the Immulite
2000 Automated Immunoassay Analyzer
(Siemens Healthcare Diagnostics Inc.,
Deerﬁeld, IL), and plasma FFAs were
measured using an in vitro enzymatic
Figure 1—Study protocol (A) and GIRs during euglycemic-hyperinsulinemic clamps (B). Each
subject was studied thrice randomly and CEU/MCE performed before and after 2-h euglycemic
insulin clamp. Plasma glucose was measured every 5 min and GIR was adjusted to maintain
euglycemia. AUC, area under the curve. *P , 0.007 vs. control.
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NEFA-HR kit (Wako Diagnostics, Rich-
mond, VA).
Statistical analysis
All data are presented as mean 6 SEM.
Statistical analyses were performed using
SigmaStat 3.1 software (Systat Software,
Inc., Chicago, IL). Each subject served as
his or her own control. Comparisons be-
tween measurements made before and
after the insulin clamp within each study
protocol and across all three studies were
done using either paired Student t test,
one-way ANOVA, or two-way repeated-
measures ANOVA where appropriate. A
P value , 0.05 was considered statisti-
cally signiﬁcant.
RESULTS—All subjects were normo-
tensive (systolic 128 6 2m m H ga n dd i -
astolic 73 6 2 mmHg) and had normal
total cholesterol (172 6 12 mg/dL), tri-
glyceride (70 6 9m g / d L ) ,L D Lc h o l e s -
terol (101 6 8m g / d L ) ,a n dH D L
cholesterol (59 6 5 mg/dL) concentra-
tions. Table 1 shows the plasma glucose,
insulin, and FFA concentrations at base-
line and after 2-h of insulin infusion. In-
sulin infusion during the control study
raisedplasmainsulinconcentrationstolev-
elsseenpostprandially.Thiswasassociated
with a signiﬁcant decrease in plasma FFA
concentrations. In the lipid protocol, lipid
infusion raised basal plasma FFA concen-
trationsbysixfold.Althoughitdidnotalter
basal plasma glucose concentrations, it did
increase basal plasma insulin levels by
.60% (P , 0.001). Insulin infusion de-
creased plasma FFA concentrations by
;1.3 mEq/L (31%, P , 0.001) during
the lipid study. Salsalate pretreatment
plus lipid infusion similarly did not alter
plasmaglucoseconcentrations.Plasmain-
sulin concentrations trended up further
(P=0.08),butplasmaFFAconcentrations
were signiﬁcantly lower (P , 0.04) com-
pared withthe values obtained inthe lipid
alone study. Plasma FFA concentrations
were similarly decreased after insulin in-
fusion (24%, P = 0.001).
During the saline control study, the
steady-state glucose infusion rates (GIRs)
varied from 2.4 to 8.6 (average 5.6 6 0.7)
mg/kg/min across individuals. Figure 1B
showstheGIRsduring theentire 120min
of insulin infusion for all three protocols.
Lipid infusion signiﬁcantly decreased the
GIRrequiredtomaintaineuglycemia.The
steady-state GIR decreased from 5.6 6
0.7 to 4.5 6 0.5 mg/kg/min (P ,
0.001), and the overall GIR area under
the curve declined by 20% (P , 0.007),
indicating acute insulin resistance in-
duced by lipid infusion. Salsalate treat-
ment did not signiﬁcantly alter the
steady-state GIR (4.8 6 0.6 mg/kg/min,
P , 0.04 vs. control), but it did signiﬁ-
cantly improve the GIR area under the
curve (back to the levels that were not
statistically signiﬁcantly different from
the control study [P =0 . 2 ] ) .T h i si m -
provement in GIR was most evident dur-
ing the ﬁrst 60–90 min when the GIR
initially tracked that of the control study.
However, it then diverged and ap-
proached that observed in the lipid study
by 120 min.
Figure 2A–C s h o w st h ec h a n g e so f
skeletal muscle microvascular parameters
in all three studies. Similar to our previ-
ous reports (6,7), insulin potently in-
creased muscle MBV and MBF without
affecting MFV. Lipid infusion completely
blocked these insulin-mediated increases
in MBV and MBF. Salsalate pretreatment
for 4 days prior to lipid infusion restored
insulin-mediated increases near com-
pletely in MBV (P = 0.06) and completely
in MBF.
Considering the cardiac microcircu-
lation, Fig. 3A–C shows insulin infusion
signiﬁcantly increased myocardial MBV
and MBF without changing MFV. As in
skeletal muscle, these insulin effects were
abolished by lipid infusion. With salsalate
pretreatment, both MBV and MBF values
post–insulininfusionweresimilartothose
values seen in the control study. However,
inthisstudytherewasanelevationofMBV
(P=0.1)andMBF(P,0.03)seenpriorto
giving insulin, and there was no statistical
signiﬁcance between the pre- and postin-
sulin values.
CONCLUSIONS—The current study
examined the effects of salsalate on FFA-
induced microvascular and metabolic
insulin resistance in humans, using a
combination of contrast ultrasonography
and hyperinsulinemic-euglycemic clamp
methods. Our results indicate that high
plasma concentrations of FFAs induce
bothmicrovascularandmetabolicinsulin
resistance and that pretreatment with
salsalate prevents FFA-induced muscle
microvascular insulin resistance and at-
tenuates whole body metabolic insulin
resistance in a group of healthy young
adults.
FFAs cause endothelial insulin resis-
tance via activation of IKKb (1). In cul-
tured ECs, FFAs increase IKKb activity
and inhibit insulin-mediated eNOS phos-
phorylation and NO production (1).
Salsalate is a potent anti-inﬂammatory
drug (10), and our observation that
salsalate prevents FFA-induced microvas-
cular insulin resistance and attenuates
whole body metabolic insulin resistance
strongly suggests that in humans, FFAs
cause microvascular insulin resistance
via an inﬂammation-mediated pathway,
whichcontributestothemetabolicinsulin
resistance. This is clinically signiﬁcant
because treatment with either aspirin or
salsalate improves insulin resistance and
glycemic control in animals (4,11,12),
and clinical trials also have shown prom-
ising results. Indeed, studies in obese
humans have shown that salsalate treat-
ment signiﬁcantly improves glycemia,
decreases circulating C-reactive protein,
and increases insulin-mediated glucose
disposal (13,14). Salsalate treatment of
patients with type 2 diabetes for 14 weeks
signiﬁcantly decreases glycated hemo-
globin levels and improves circulating
triglyceride and adiponectin concentra-
tions (15).
In the current study, acute elevation
of plasma FFA concentrations abolished
insulin-mediated increasesinskeletal and
Table 1—Plasma substrate concentrations during insulin clamp
Control Lipid Salsalate + lipid
Basal 120 min Basal 120 min Basal 120 min
Plasma glucose (mmol/L) 5.1 6 0.1 4.4 6 0.1* 5.1 6 0.1 4.4 6 0.1* 5.0 6 0.1 4.5 6 0.1*
Insulin (pmol/L) 29 6 53 2 7 6 22** 48 6 8# 396 6 77** 74 6 15## 466 6 43**
FFA (mEq/L) 0.7 6 0.1 0.2 6 0.1** 4.2 6 0.4# 2.9 6 0.3** 3.2 6 0.3#& 2.4 6 0.3***
*P , 0.0001, **P , 0.001, ***P = 0.001 vs. respective basal; #P , 0.001, ##P , 0.005 vs. control basal; &P , 0.04 vs. lipid control.
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Salsalate and microvascular insulin resistancecardiac muscle microvascular recruitment
and decreased insulin-stimulated whole
bodyglucosedisposal.Thisisinlinewith
our previous reports in humans (6,7)
and a previous report in rats (9). Strong
evidence has conﬁrmed that FFAs inhibit
insulin signaling through the PI3-kinase
pathway in both vasculature and muscle.
In humans, high plasma concentrations









vascular reactivity. In addition, insulin
has been shown to induce eNOS (20),
and an insulin-resistant state may impair
vasodilation by blocking insulin-mediated
induction of eNOS. It is interesting that
salsalate treatment prevented the lipid-
induced decrease in whole body glucose
disposal during the ﬁrst 60–90 min only.
Towardthelast30minofclamp,insulin-
stimulated glucose disposal rates were
not different from the lipid group. That
pretreatmentwithsalsalaterestoredinsulin
response in muscle MBF suggests salsalate
treatment completely prevented lipid-
induced microvascular insulin resistance
in muscle. Thus, the resolution of micro-
vascular insulin resistance may have con-
tributed to the early phase improvement
of metabolic insulin sensitivity, whereas
later muscle insulin resistance (without
the vascularcomponent) might havepre-
vailed. Indeed, previous studies have
demonstrated that insulin-mediated cap-
illary recruitment contributes to 40% of
insulin-mediated whole body glucose
disposal and that vascular insulin resis-
tance might be more important as a de-
terminant of the rate of onset of insulin
action (8,21).
Although salsalate treatment com-
pletely restored insulin responsiveness
in skeletal muscle microcirculation, in the
heart,therewasnodifferenceineitherMBV
or MBF before and after insulin infusion
during the Intralipid plus salsalate admis-
sion. However, the absolute post–insulin
infusion values were similar to those seen
i nt h ei n s u l i nc o n t r o ls t u d y .T h i sw a sm o s t
likelysecondarytothebaselineincreasesin
both MBV (P = 0.06) and MBF (P =0 . 0 3 )
induced by lipid infusion in the setting of
salsalate treatment. In the salsalate plus
lipid protocol, basal MBV was 21 6 9%
higher than in the saline control subjects
and only 4% less than the insulin-treated
control subjects in the saline control pro-
tocol. Thus, the increase in MBV induced
by lipid infusion after salsalate treatment
may have preempted any insulin effect.
The mechanisms underlying these in-
creases in MBV and MBF in the heart are
unknown. We and others have previously
reported that lipid infusion increases basal
cardiac (6) and total leg blood ﬂow
(18). It is interesting that the addition of
salsalate to lipid infusion further en-
hanced basal cardiac MBF. The underly-
ing mechanisms remain unclear. Given
that plasma insulin concentrations in-
creased signiﬁcantly in the basal state, it
is likely that both insulin and FFAs may
have contributed to this increase in basal
ﬂow.
Inasmuch as salsalate is capable of
increasing insulin secretion (14,22) and
the plasma insulin trended higher during
thesalsalatepluslipidstudythanthelipid
alone study, the improved microvascular
and metabolic responses could be sec-
ondary to increased circulating insulin
concentrations. Indeed, the signiﬁcantly
lower preclamp FFA concentrations are
also suggestive of possible insulin effect.
However, this probability is rather low
because both the preclamp (P = 0.08)
and postclamp (P = 0.51) insulin concen-
trations were not signiﬁcantly higher
during the salsalate plus lipid admission
than the lipid alone admission. In addi-
tion, insulin increased muscle MBV only
by ;25% when its concentrations were
raised by 10-fold in the current study.
The concentrations of FFAs used in
the current study are higher than those
observed in insulin-resistant states. We
opted to use high concentrations of FFAs
becauseinthepast,wehavedemonstrated
that FFAs at these concentrations blocked
insulin- and mixed meal–induced muscle
microvascular recruitment in healthy
humans (6,7). Thus, it is very much likely
that salsalate treatment could be more ef-
fective in the setting of low plasma con-
centrations of FFAs.
In conclusion, high plasma concen-
trations of FFAs cause muscle microvas-
cular and whole body metabolic insulin
resistance in healthy human adults.
Salsalate treatment blocked FFA-induced
microvascular insulin resistance, which
was associated with a signiﬁcant im-
provement in whole body insulin sensi-
tivity. Thus, our data suggest that FFAs
cause microvascular insulin resistance and
dysfunction likely via an inﬂammation-
mediated mechanism and that this con-
tributes to metabolic insulin resistance in
humans.Treatmentsaimedatinﬂammation
Figure 3—Myocardial MBV (A), MFV (B),
and MBF (C) at baseline (open bar) and at
end of 120-min insulin infusion (black bar).
Compared with baseline, *P = 0.01, **P =
0.001. Compared with control baseline, #P =
0.03.
Figure 2—Skeletal muscle MBV (A), MFV (B),
andMBF(C)atbaseline(openbar)andatendof
120-min insulin infusion (black bar). Compared
with respective baseline, *P =0 . 0 1 ,* * P = 0.02.
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Chai and Associatesinhibition may afford an opportunity to
improve diabetes control and prevent
cardiovascular complications in patients
with type 2 diabetes.
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